Oppenheimer Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $265

Oppenheimer analyst Hartaj Singh maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $230 to $265.

Benzinga · 01/08/2020 16:04

Oppenheimer analyst Hartaj Singh maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $230 to $265.